miR-145 Inhibits Mitochondrial Function of Ovarian Cancer by Targeting ARL5B

Shuo Zhao  
The First Affiliated Hospital of Xi’an Jiaotong University  

Yun Zhang  
The First Affiliated Hospital of Xi’an Jiaotong University  

Meili Pei  
The First Affiliated Hospital of Xi’an Jiaotong University  

Lei Wu  
The First Affiliated Hospital of Xi’an Jiaotong University  

Jie Li  
First Affiliated Hospital of Xi’an Jiaotong University  
lijiex64@126.com  
https://orcid.org/0000-0002-4433-5393

Research

Keywords: miR-145, ARL5B, mitochondrial function, ovarian cancer

DOI: https://doi.org/10.21203/rs.3.rs-106451/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Metabolic reprogramming refers to the transformation of the whole metabolic network including glycolysis and mitochondrial metabolism, mainly manifested in Warburg effect and mitochondrial metabolic reprogramming. The roles of miR-145 in glycolysis have been established in ovarian cancer cells. However, its roles in mitochondrial metabolic reprogramming are still unclear. This study aims to identify whether miR-145 regulates mitochondrial metabolic reprogramming in ovarian cancer cells. First, functional experiment showed that overexpression of miR-145 inhibited mitochondrial function in ovarian cancer cells, evident by the decreased mtDNA copy numbers, ATP level, mitochondrial membrane potential, and the expression levels of mitochondrial markers. Mechanistically, miR-145 inhibited mitochondrial function by targeting ARL5B directly. Furthermore, miR-145 overexpression decreased ARL5B expression in ovarian cancer tissue subcutaneous tumors of nude mice. In conclusion, we have highlighted that miR-145 inhibits mitochondrial function and achieves this by targeting ARL5B directly for the first time. The results provides a more adequate theoretical basis for understanding the molecular pathology of ovarian cancer, and provides the necessary basic data for miR-145 as a potential diagnosis and treatment target for ovarian cancer.

1. Introduction

Ovarian cancer is one of the most common malignant tumors in women, and its mortality rate ranks first in gynecological tumors[1]. The main treatment of ovarian cancer is surgical treatment, supplemented by intravenous chemotherapy or intraperitoneal chemotherapy or combined treatment[2]. However, positive treatment did not achieve satisfactory results, the molecular mechanism and effective diagnostic biomarkers for this cancer have yet to be identified.

For many years, cancer has been regarded as an uncontrolled proliferative disease. Although metabolic changes have been studied in tumor cells, it has been considered as a secondary phenomenon. Recently, more and more evidences suggest that tumor is a primary metabolic disease[3, 4]. The metabolic research of tumor cells was first proposed by Otto Warburg, who found that most tumor cells still choose glycolysis pathway to provide energy and raw materials for biosynthesis even under aerobic conditions[5]. In fact, the complexity of the regulation of metabolic balance in tumor cells is far beyond Warburg's original assumption[6, 7]. Increasing evidence has shown that some cancer subtypes may rely more on their intact mitochondrial respiration, which plays a pivotal role in tumor progression, and the molecular mechanisms underlying metabolic reprogramming of cancer cells has become an important topic in cancer research[8].

MicroRNAs (miRNAs) are a class of endogenous non coding small RNAs with a length of about 22 nt, which widely exist in eukaryotes[9]. miRs are closely related to tumors and act as oncogenes or tumor suppressor genes. It plays an important role in the growth, proliferation, differentiation, apoptosis, invasion and metastasis of tumor cells[10, 11]. We and other studies have shown that miR-145 is low expressed in the ovarian cancer and plays an anti-cancer role. miR-145 inhibits ovarian cancer cells
migration and invasion by targeting FSCN1 and FLNB[12, 13]. inhibits glutamine metabolism through c-
myc/GLS1 pathways[14], and is involved in regulation of the Warburg effect through the miR-133b/PKM2
signaling pathway[15]. However, it remains unclear whether miR-145 participates in mitochondrial
metabolic reprogramming in ovarian cancer.

In the current study, functional experiments revealed that miR-145 inhibited mitochondrial function.
Mechanistic research showed that miR-145 regulated the mitochondrial function through targeting
ARL5B (ADP-ribosylation factorlike 5B) directly. This study provides the necessary basic data for the
transformation of miR-145 to clinical application.

2. Materials And Methods

2.1 Cell culture

The human ovarian cancer cell line SKOV3 was obtained from the Shanghai Cell Bank of Chinese
Academy of Sciences (Shanghai, China); 3AO was obtained from the Shandong Academy of Medical
Sciences (Jinan, China). Cells were maintained in RPMI 1640 medium(Gibco-BRL, Gaithersburg, MD, USA)
supplemented with 10% (v/v) FBS at 37 °C under a humidified 5% CO2 atmosphere.

2.2 Microrna Mimics Transfection

miR-145 mimic and control mimic were purchased from Ribo-Bio Biotechnology Co. Ltd(Guangzhou,
China), and transfected instantaneously using Roche's X-treme GENE siRNA transfection reagent(Roche,
Indianapolis, IN, USA). The cells were inoculated into 6-well plates with 3 × 10^5 holes. After 24 hours, the
degree of cell fusion reached 30%-40%. SKOV3 and 3AO cells were transiently transfected with 60 nM
miR-145 mimic or negative control using the X-treme GENE siRNA Transfection Reagent following the
manufacturer’s protocol.

2.3 Plasmids Transfection

Human ARL5B expression vector pDEST47-ARL5B was obtained from Addgene (Boston, MA, USA). The
cells were inoculated into 6-well plates with 3 × 10^5 holes. After 48 hours, cells were until 70%-90% conuency and transiently transfected with pDEST47-ARL5B or empty vector using the X-treme GENE HP DNA Transfection Reagent (Roche, Indianapolis, IN, USA) following the manufacturer’s protocol.

2.4 Real-time PCR

Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer's instructions. RNA reverse transcription was performed using RevertAid first strand cDNA
synthesis Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). The primer dry powder was diluted to
10 µM working concentration, and the real-time quantitative PCR using a SYBR Premix Ex Taq™ II kit
(Takara, Dalian, China) on a CFX96 real-time PCR system (Bio-Rad, Hercules, CA, USA), and the reaction
solution was prepared using the reverse transcription DNA as template according to the following system:
SYBY Green 10µL, upstream primer 0.4µL, downstream primer 0.4µL, DNA template 2.0µL, ddH2O 7.2µL. In each experiment, a negative control group without template was set up. Each sample was set up with three multiple holes and repeated for three times. RQ values were calculated by $2^{-\Delta\Delta Ct}$ method to compare the differences of gene expression between each group. miR-145 were normalized to small nuclear U6, while ARL5B was normalized to the gene β-actin. The following primer sequences were used:

ARL5B forward: 5’- AGTGGGACTGGATAATGCAGGG-3’;
ARL5B reverse: 5’- ATCGCAGAGACTCCTGACCACC-3’;
β-actin forward: 5’-TCCCTGGAGAAGAGCTACGA-3’;
β-actin reverse: 5’-AGCCTGTGTGCTTTGGCGTACAG-3’.

**2.5 Western Blotting**

The concentration of total protein in cells was determined by the BCA-200 Protein Assay kit (Pierce, Rockford, IL, USA). Electrophoretic gels were prepared for SDS-PAGE. After electrophoresis, cut the adhesive strip to the appropriate size, balance with the membrane transfer buffer, cut the filter paper and NC membrane of the same size as the adhesive strip in advance, and immerse it in the transfer membrane buffer for 10 min. At the end of membrane transfer, the power supply was cut off and the membrane was taken out for immunoblotting. Decolorization on the shaking table of the 5% skim milk powder TBST buffer at room temperature to seal the 1H on the sulfate. Add anti-ARL5B antibody (1:500, Abcam; Cambridge, MA, USA), anti-SDHA, anti-HSP60, anti-Cytc (1:500, Cell Signaling Technology; Beverly, MA, USA), anti-β-actin (1:1000, Cell Signaling Technology; Beverly, MA, USA), incubate overnight at 4 C, add 1:2000 horseradish peroxidase labeled goat anti-rabbit antibody(Pierce Company, USA) or 1:2000 horseradish peroxidase labeled goat anti-mouse antibody (Pierce Company, USA) Incubation at room temperature for 1 hour. Electro-chemiluminescence (ECL) imaging. Blots were visualized using ECL reagents (Pierce, Rockford, IL, USA) by a chemiluminescence imaging system (Bio-Rad, Richmond, CA, USA).

**2.6 Mitochondria Copy Number Test**

1–3 µg RNA was reverse transcribed to cDNA using the RevertAid First Strand cDNA Synthesis Kit(Thermo Fisher Scientific Inc., Waltham, MA, USA). Mitochondrial DNA (mtDNA) was assessed by real-time quantitative PCR, using mitochondrial D-loop as target gene, normalized as 18S rRNA. The primer sequences for D-loop(F: 5’-AAGTGGCTGTGCAGACATTC-3’, R: 5’-TCTGTCTTTTGATCTGCCT-3’) and 18S rRNA (F: 5’-TCTCCTACTTTGGATAACTGTGG-3’, R: 5’-GGCGACTACCATCGAAAGTTG-3’).

**2.7 ATP Assay**

ATP concentrations were tested with enhanced ATP assay kit (Beyotime, Shanghai, China) according to the manufacturer’s protocol. For adherent cells, the culture medium was removed, and 200 µL ATP was
added into each well of 6-well plate to detect the proportion of lysate, and then directly added into the hole to lyse the cells. After pyrolysis, the supernatant was centrifuged at 4 °C for 5 min at 12000 g. The ATP detection lysate and ATP standard solution (0.5 mM) were dissolved on ice, and the ATP standard solution was diluted into appropriate concentration gradient with ATP detection lysate. Six concentrations were set as follows: 0.01 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM and 10 μM, respectively. According to the proportion of 100 μl ATP detection working solution required for each sample or standard, an appropriate amount of ATP detection working fluid was prepared. Take appropriate amount of ATP detection reagent and dilute ATP detection reagent with ATP detection diluent in the ratio of 1:5. Add the prepared 100 μL ATP detection working solution into the detection tube, place it at room temperature for 3 ~ 5 min, add 20μL sample or standard substance into the detection tube, mix it quickly with a micro pipette, and measure the RLU value with a luminometer (Promega, Madison, WI, USA) after 2 s of action. ATP levels was estimated based on the standard curve, and normalized to the cell number.

2.8 Mitochondrial Membrane Potential (jc-1)

The cells were digested with 0.25% trypsin without EDTA. After digestion, the cells were collected, centrifuged at 1200 rpm for 5 min, and the supernatant was suspended in 0.5 mL cell culture medium. Add 0.5 mL JC-1 dyeing working solution, invert for several times, mix well, and incubate in cell incubator at 37 °C for 20 minutes; during incubation, add 4 ml distilled water to every 1 mL JC-1 staining buffer (5x), and place it in ice bath. After incubation at 37 °C, the supernatant was centrifuged at 1200 rpm 4 °C for 3 minutes and the supernatant was discarded, Then washed twice with JC-1 staining buffer (1x), cells were resuspended by adding 1 mL JC-1 staining buffer (1x), centrifuged at 1200 rpm for 3 minutes, and the supernatant was discarded. The cells were resuspended with 1 mL JC-1 staining buffer (1 x), centrifuged at 4 °C for 3 minutes at 1200 rpm, and the supernatant was discarded. After resuspension with 500 UL JC-1 staining buffer (1 x), the cells were analyzed by flow cytometry.

2.9 Dual-luciferase Assay

miR-145 mimic, WT and pRL-TK were co-transfected into SKOV3 and 3AO cells. miR-145 mimic control, WT and pRL-TK were transfected into SKOV3 and 3AO cells as controls. After 24 hours, firefly signal and seaKidney fluorescence signal were read by a dual-luciferase reporter gene assay system (Promega, Madison, WI, USA), and the relative fluorescence value of seaKidney signal/firefly signal was used for comparison.

2.10 Immunohistochemistry (IHC)

Samples were fixed in 10% neutral buffered formalin, dehydrated and embedded in paraffin. The paraffin-embedded tissues were cut into five-micron-thick serial sections. Conventional dewaxing, antigenic microwave thermal retrieval, and quenching endogenous peroxidase activity were performed on sections. Primary antibodies (anti-ARL5B antibody, 1:200; Abcam, Cambridge, MA, USA) were applied to the sections at 4 °C overnight. Next, the sections were treated with secondary antibody for 30 minutes at room temperature. Polymerase auxiliary agent was then added and incubated for another 30 minutes at
room temperature and stained with 3, 3′-diaminobenzidine (DAB). Finally, the slides were counterstained with 0.02% Hematoxylin and tested by microscope.

2.11 Statistical Analysis

Each experiment was independently performed at least 3 times. The graphical presentations were performed using GraphPad Prism 5.0. Data were presented as the means ± SE and were analyzed using SPSS 22.0 software (Chicago, IL, USA). Statistical differences were tested by Chi-square test, two-tailed t-test, one-way ANOVA test or Fisher's Exact test. A value of P < 0.05 was considered to be significant.

3. Results

3.1 miR-145 inhibits mitochondrial function in ovarian cancer cells

To investigate whether miR-145 could regulate the mitochondrial function of ovarian cancer cells, qRT-PCR was performed to detect the expression of D-loop (control region displacement loop), which is the control gene of mitochondrial DNA replication. The results showed that overexpression of miR-145 (Fig. 1A) decreased the copy number of mitochondrial DNA (Fig. 1B). Then, ATP level detection results showed that overexpression of miR-145 decreased ATP levels in ovarian cancer cells (Fig. 1C). Mitochondrial membrane potential is an important indicator of mitochondrial membrane integrity. We detected the mitochondrial membrane potential of miR-145-overexpression cells by JC-1 staining. Results as shown in Fig. 1D, overexpression of miR-145 decreased mitochondrial membrane potential. Furthermore, the protein expression of mitochondrial markers was detected. The related markers include: SDHA, a key component of TCA cycle and electron transport chain; HSP60, which plays an important role in protein folding into mitochondria; CytC, a conserved electron transport protein located in the inner space of mitochondria. Western blotting results demonstrated that overexpression of miR-145 down regulated the expression of SDHA, HSP60 and CytC (Fig. 1E). Taken together, these data indicated that miR-145 inhibited mitochondrial function in ovarian cancer cells.

3.2 ARL5B is a target of miR-145

We further detected the effect of miR-145 on the expression of ARL5B. The results showed that overexpression of miR-145 inhibited the mRNA expression of ARL5B (Fig. 2A), and the protein level was consistent with mRNA level (Fig. 2B). We predicted the interaction between miR-145 and 3'-UTR of ARL5B according to the TargetScan website (http://www.targetscan.org/mamm_31/), Then dual-luciferase reporter assay verified that miR-145 might negatively regulate ARL5B expression by directly binding to the sequence of ARL5B 3'UTR (Fig. 2C). Taken together, these data indicated that ARL5B was a target of miR-145.

3.3 miR-145 inhibits mitochondrial function by depressing miR-145 in ovarian cancer cells

To further clarify whether miR-145 inhibited mitochondrial function through suppressing ARL5B, we evaluated the mtDNA copy number, ATP production, and mitochondrial activity in different groups,
including NC mimic, miR-145 mimic, and miR-145 mimic + ARL5B. The results showed overexpression of miR-145 inhibited the mtDNA copy number (Fig. 3B), ATP production (Fig. 3C), and mitochondrial activity (Fig. 3D), and after overexpression of ARL5B (Fig. 3A), this inhibitory effect was reversed. These results demonstrated that miR-145 inhibited mitochondrial function by depressing miR-145 in ovarian cancer cells.

3.4 Expression of miR-145 and ARL5B in ovarian cancer tissue subcutaneous tumors of nude mice

In our previous studies, we found that miR-145 inhibited growth of xenografts of ovarian cancer in nude mice[12]. Here, to further investigate whether miR-145 could regulate mitochondrial function of SKOV3 cells in vivo, we analyzed the mRNA expression levels of ARL5B and miR-145 by real-time PCR, which showed decreased mRNA levels of ARL5B when miR-145 was upregulated in vivo (Fig. 4A), and immunohistochemical analysis of ARL5B in miR-145-up mice was lower than that in the control group (Fig. 4B). Collectively, these in vivo findings coincide with the in vitro changes observed in the cell models, showing that miR-145 inhibited ARL5B expression in ovarian cancer.

4. Discussion

Metabolic reprogramming of tumor cells provides energy and material for tumor growth, invasion and metastasis, and promotes the occurrence and development of tumors. Therefore, it is considered as one of the important characteristics of tumor occurrence and development[6, 16]. Metabolic reprogramming refers to the transformation of the whole metabolic network including glycolysis and mitochondrial metabolism, mainly manifested in Warburg effect and mitochondrial metabolic reprogramming[17, 18]. In recent years, more and more studies have found that mitochondria are not bystanders in the process of tumor development, but some tumor cells are more dependent on mitochondrial metabolism[19, 20]. Mitochondrial metabolism is not only the energy metabolism center of tumor cells, but also an important hub of many biological macromolecular synthesis pathways[19, 20]. miR-145 is involved in regulation of the Warburg effect through the miR-133b/PKM2 signaling pathway[15] and targeting HK2 directly[21], which strongly suggests that miR-145 participates in metabolic reprogramming. However, the mechanism whereby miR-145 participates in tumor mitochondrial function has not been clarified.

MicroRNAs are widely distributed in eukaryotes. They can bind to the 3'-UTR of their target gene mRNA to degrade mRNA and inhibit their translation[22, 23]. Our previous findings confirmed that miR-145 inhibited ovarian cancer growth in vivo and in vitro[12]. MiR-145 blocked epithelial-mesenchymal transition of ovarian cancer cells by targeting FSCN1[12], inhibited glutamine metabolism by targeting c-myc[14], inhibited the Warburg effect by targeting HK2[21], and regulated RNA methylation by targeting YTHDF2[24]. In order to test whether miR-145 was involved in the regulation of mitochondrial function, we then detected mitochondrial biogenesis by assessing the mtDNA copy number, ATP production, mitochondrial membrane potential, and mitochondrial-associated protein expression levels. The results suggested that MiR-145 may act as an oncogene and could play an important role in mitochondrial metabolism in ovarian cancer cells.
Although it has been verified that miR-145 may modulate mitochondrial metabolism in ovarian cancer, the underlying mechanism remains unclear. We predicted that ARL5B was the target gene of miR-145 by Targetscan and confirmed by dual-luciferase reporter assay. ARL5B has been recognized as a member of the ADP ribosylation factor-like (ARL) family belonging to the RAS superfamily\[25–27\]. Previous studies have demonstrated that ARL5B overexpression facilitated lysosome motility, resulting in lysosome dispersion and accumulation at the cell periphery\[28, 29\]. The present research detected that decreased lysosomal outward trafficking resulted in inhibited cancer cell invasion\[30\]. ARL5B silencing reduced lysosome dispersion and subsequently decreased cell invasion in prostate cancer\[31\]. These results suggested that ARL5B plays a role in promoting cancer in cancer. However, the role of ARL5B in ovarian cancer remains unclear.

In order to investigate whether miR-145 inhibited mitochondrial function by targeting ARL5B in ovarian cancer cells, we confirmed the mtDNA copy number, ATP production, and mitochondrial activity in different groups. The results showed overexpression of miR-145 inhibited the mtDNA copy number, ATP production, and mitochondrial activity, and after overexpression of ARL5B, this inhibitory effect was reversed.

5. Conclusions

In conclusion, we have highlighted that miR-145 inhibits mitochondrial function and achieves this by targeting ARL5B directly for the first time. The results provides a more adequate theoretical basis for understanding the molecular pathology of ovarian cancer, and provides the necessary basic data for miR-145 as a potential diagnosis and treatment target for ovarian cancer.

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests
Funding

This work was supported by National Natural Science Foundation of China(No.81702577), and Natural Science Basic Research Program of Shaanxi(No. 2018JQ8035), and the Fundamental Research Funds for the Central Universities(No. XZY012019105).

Authors' contributions

Jie Li conceived and designed the experiments. Shuo Zhao, Lei Wu and Yun Zhang performed the experiments. Jie Li, Shuo Zhao and Meili Pei analyzed the data. Jie Li, Shuo Zhao, Lei Wu and Yun Zhang wrote the paper. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Stewart C, Ralyea C, Lockwood S: Ovarian Cancer: An Integrated Review. Seminars in oncology nursing 2019, 35(2):151-156.
2. Jiang Y, Wang C, Zhou S: Targeting tumor microenvironment in ovarian cancer: Premise and promise. Biochimica et biophysica acta Reviews on cancer 2020, 1873(2):188361.
3. Devic S: Warburg Effect - a Consequence or the Cause of Carcinogenesis? Journal of Cancer 2016, 7(7):817-822.
4. Coller HA: Is cancer a metabolic disease? The American journal of pathology 2014, 184(1):4-17.
5. Soga T: Cancer metabolism: key players in metabolic reprogramming. Cancer science 2013, 104(3):275-281.
6. Ru P, Williams TM, Chakravarti A, Guo D: Tumor metabolism of malignant gliomas. Cancers 2013, 5(4):1469-1484.
7. Koppenol WH, Bounds PL, Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nature reviews Cancer 2011, 11(5):325-337.
8. Zong WX, Rabinowitz JD, White E: Mitochondria and Cancer. Molecular cell 2016, 61(5):667-676.
9. Lu TX, Rothenberg ME: MicroRNA. The Journal of allergy and clinical immunology 2018, 141(4):1202-1207.
10. Iorio MV, Croce CM: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO molecular medicine 2012, 4(3):143-159.
11. Hayes J, Peruzzi PP, Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. Trends in molecular medicine 2014, 20(8):460-469.
12. Li J, Lu J, Ye Z, Han X, Zheng X, Hou H, Chen W, Li X, Zhao L: 20(S)-Rg3 blocked epithelial-mesenchymal transition through DNMT3A/miR-145/FSCN1 in ovarian cancer. Oncotarget 2017,
13. Li J, Zhang S, Wu L, Pei M: Interaction between LncRNA-ROR and miR-145 contributes to epithelial-mesenchymal transition of ovarian cancer cells. *General physiology and biophysics* 2019, 38(6):461-471.

14. Li J, Li X, Wu L, Pei M, Li H, Jiang Y: miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells. *Cell biology international* 2019, 43(8):921-930.

15. Li J, Zhang S, Zou Y, Wu L, Pei M, Jiang Y: miR-145 promotes miR-133b expression through c-myc and DNMT3A-mediated methylation in ovarian cancer cells. *Journal of cellular physiology* 2020, 235(5):4291-4301.

16. Hirschey MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, Jones LW, Ko YH, Le A, Lea MA et al: Dysregulated metabolism contributes to oncogenesis. *Seminars in cancer biology* 2015, 35 Suppl:S129-S150.

17. Sun L, Suo C, Li ST, Zhang H, Gao P: Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. *Biochimica et biophysica acta Reviews on cancer* 2018, 1870(1):51-66.

18. Li C, Zhang G, Zhao L, Ma Z, Chen H: Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer. *World journal of surgical oncology* 2016, 14(1):15.

19. Dong LF, Neuzil J: Mitochondria in cancer: why mitochondria are a good target for cancer therapy. *Progress in molecular biology and translational science* 2014, 127:211-227.

20. Chen EI: Mitochondrial dysfunction and cancer metastasis. *Journal of bioenergetics and biomembranes* 2012, 44(6):619-622.

21. Zhang S, Pei M, Li Z, Li H, Liu Y, Li J: Double-negative feedback interaction between DNA methyltransferase 3A and microRNA-145 in the Warburg effect of ovarian cancer cells. *Cancer science* 2018, 109(9):2734-2745.

22. Kiselev FL: [MicroRNA and cancer]. *Molekuliarnaia biologiia* 2014, 48(2):232-242.

23. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nature cell biology* 2009, 11(3):228-234.

24. Li J, Wu L, Pei M, Zhang Y: YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. *Journal of ovarian research* 2020, 13(1):111.

25. Gillingham AK, Munro S: The small G proteins of the Arf family and their regulators. *Annual review of cell and developmental biology* 2007, 23:579-611.

26. Garg S, Sharma M, Ung C, Tuli A, Barral DC, Hava DL, Veerapen N, Besra GS, Hacohen N, Brenner MB: Lysosomal trafficking, antigen presentation, and microbial killing are controlled by the Arf-like GTPase Arl8b. *Immunity* 2011, 35(2):182-193.

27. Rosa-Ferreira C, Munro S: Arl8 and SKIP act together to link lysosomes to kinesin-1. *Developmental cell* 2011, 21(6):1171-1178.
28. Bagshaw RD, Callahan JW, Mahuran DJ: The Arf-family protein, Arl8b, is involved in the spatial distribution of lysosomes. *Biochemical and biophysical research communications* 2006, 344(4):1186-1191.

29. Rosa-Ferreira C, Sweeney ST, Munro S: The small G protein Arl8 contributes to lysosomal function and long-range axonal transport in Drosophila. *Biology open* 2018, 7(9).

30. Rafn B, Nielsen CF, Andersen SH, Szyniarowski P, Corcelle-Termeau E, Valo E, Fehrenbacher N, Olsen CJ, Daugaard M, Egebjerg C et al: ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. *Molecular cell* 2012, 45(6):764-776.

31. Dykes SS, Gray AL, Coleman DT, Saxena M, Stephens CA, Carroll JL, Pruitt K, Cardelli JA: The Arf-like GTPase Arl8b is essential for three-dimensional invasive growth of prostate cancer in vitro and xenograft formation and growth in vivo. *Oncotarget* 2016, 7(21):31037-31052.